Niacinamide

Verify with FDA CVM →

48 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
48
Total Reports
5
Deaths Reported
1040.0%
Death Rate

Active Ingredients

Niacinamide

Administration Routes

UnknownOralOphthalmic

Species Affected

Dog 47
Human 1

Most Affected Breeds

Shepherd Dog - German 5
Retriever - Labrador 4
Dachshund (unspecified) 3
Retriever - Golden 3
Pit Bull 2
Schnauzer - Miniature 2
Crossbred Canine/dog 2
Dog (unknown) 2
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 2
Sheepdog - Shetland 1

Most Reported Reactions

Diarrhoea 7
Lethargy (see also Central nervous system depression in 'Neurological') 6
Vomiting 6
Lack of efficacy - NOS 5
Seizure NOS 5
Anorexia 5
Not eating 4
Elevated alanine aminotransferase (ALT) 4
Other abnormal test result NOS 4
Leucocytosis NOS 4
Lethargy (see also Central nervous system depression in Neurological) 4
Emesis (multiple) 3

Outcome Breakdown

Ongoing
25 (52.1%)
Outcome Unknown
7 (14.6%)
Recovered/Normal
6 (12.5%)
Recovered with Sequela
5 (10.4%)
Died
3 (6.3%)
Euthanized
2 (4.2%)

Data Summary

Metric Value
Total adverse event reports 48
Reports involving death 5
Case-fatality rate (reported events) 1040.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Niacinamide Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 48 adverse event reports referencing Niacinamide, including 5 reports in which the animal died — a 1040.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Niacinamide. Reported administration routes include Unknown, Oral, Ophthalmic. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Niacinamide reports are Dog (47 reports), Human (1 reports), with Dog accounting for the largest share. Within those species, Shepherd Dog - German (5), Retriever - Labrador (4), Dachshund (unspecified) (3) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Niacinamide are Diarrhoea (7), Lethargy (see also Central nervous system depression in 'Neurological') (6), Vomiting (6), Lack of efficacy - NOS (5). Of the 48 reports with a coded outcome, Ongoing is the leading category at 52.1%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Niacinamide.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial